Roh ME, ter Kuile FO, Rerolle F, et al. - Researchers investigated if non-malarial benefits for birth outcomes of sulfadoxine-pyrimethamine are greater than those of dihydroartemisinin-piperaquine, and examined if antimalarial benefits for birth outcomes in correlation with dihydroartemisinin-piperaquine were greater than those with sulfadoxine-pyrimethamine. They described treatment as random assignment to sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine prior to pooling individual participant-level data from 1,617 HIV-uninfected pregnant women in Kenya (one trial; n = 806) and Uganda (two trials; n = 811). Overall, higher birthweight was reported among neonates of women randomly assigned to sulfadoxine-pyrimethamine vs those assigned to dihydroartemisinin-piperaquine (mean difference 69 g), despite evidence of lower placental malaria infection in the dihydroartemisinin-piperaquine group. Per mediation analyses, sulfadoxine-pyrimethamine provided a greater non-malarial effect than did dihydroartemisinin-piperaquine, whereas dihydroartemisinin-piperaquine provided a slightly larger antimalarial effect than did sulfadoxine-pyrimethamine (8 g, −9 to 26), although more frequent dosing raised the antimalarial effect (31 g, 3 to 60). These findings suggest that IPTp with sulfadoxine-pyrimethamine have potent non-malarial effects on birthweight.